Tazverik is being pulled from market. What patients should do now
FDA says Tazverik is being withdrawn from the U.S. market after new safety data showed a higher-than-expected rate of new blood cancers. Here is what patients and families should do next.
The FDA says Tazverik (tazemetostat) is being voluntarily withdrawn from the U.S. market after new safety data showed a higher-than-expected rate of new blood cancers in a confirmatory study. The drug had been used for some adults and teens with epithelioid sarcoma and for some adults with relapsed or refractory follicular lymphoma.
If you or a family member takes Tazverik, the most important next step is to contact the oncology team promptly about refills, monitoring, and treatment alternatives. Do not stop, restart, or change a cancer medicine on your own unless your treating clinician tells you how to do it safely.
What the FDA announced in May 2026
In a safety alert dated May 11, 2026, the FDA said Tazverik would be voluntarily withdrawn from the market because the agency concluded that the drug’s risks now outweigh its benefits. The withdrawal affects the approved U.S. uses that had been granted under accelerated approval.
Before this withdrawal, FDA-approved labeling said Tazverik could be used for adults and certain teens age 16 and older with metastatic or locally advanced epithelioid sarcoma that could not be completely removed with surgery. It was also approved for certain adults with relapsed or refractory follicular lymphoma.
The FDA also said expanded-access programs for Tazverik would be discontinued. For patients, that means access and refill questions may need to be sorted out quickly with the treating cancer team, specialty pharmacy, and insurer.
What safety signal changed the picture
The concern was not entirely new. Earlier FDA prescribing information already warned about a risk of secondary malignancies, including myelodysplastic syndrome and acute myeloid leukemia. But the newer confirmatory data were more serious than expected.
According to the FDA, the ongoing SYMPHONY-1 confirmatory study looked at Tazverik in combination with lenalidomide plus rituximab in people with relapsed or refractory follicular lymphoma. As of March 6, 2026, the FDA said 18 of 318 patients treated with Tazverik in that study developed hematologic second primary malignancies, compared with no reported events in the control arm.
FDA said the most common new blood cancers were myelodysplastic syndrome and acute myeloid leukemia. Some cases started as early as about 7.5 months after treatment began. Most happened after one to three years of treatment, and some were found after treatment had already stopped. The agency said this was serious enough that the study stopped enrollment and Tazverik treatment was discontinued for patients receiving it in the trial.
One important point for readers: this was a study signal, not a prediction of what will happen to any one person. But it was strong enough that FDA and the sponsor moved ahead with market withdrawal.
Symptoms that could matter
Because the reported problems involve low blood counts and blood cancers, warning signs can look nonspecific at first. The American Cancer Society lists symptoms such as unusual tiredness or weakness, pale skin, shortness of breath, frequent or severe infections, easy bruising or bleeding, nosebleeds, bleeding gums, fever, and bone pain.
Call your oncology team promptly if any of those symptoms are new, worsening, or hard to explain. Seek urgent or emergency care right away for severe shortness of breath, chest pain, major bleeding, confusion, or a high fever with signs of infection.
What patients should do today
- Contact your oncology team soon. Ask how the withdrawal affects your current plan, next refill, and follow-up schedule.
- Do not make a solo medication change. MedlinePlus notes that tazemetostat has been discontinued in the U.S., but it also says not to stop taking it without talking to your doctor.
- Ask whether you need lab work. Your clinician may want blood counts or other monitoring, especially if you have new symptoms.
- Check supply and coverage. Ask your pharmacy and insurer what happens next. Substitute treatments, prior authorization rules, and out-of-pocket costs can vary by plan and by diagnosis.
- Bring a full medicine list to your next visit. Treatment changes can affect supportive medicines, drug interactions, and timing.
What is still uncertain
This withdrawal does not answer every question for every patient. It does not tell you which replacement treatment is best, how quickly your own plan may change, or whether your doctor will recommend a different drug, closer monitoring, or a different care setting. Those decisions depend on the exact cancer, past treatments, mutation status, current disease control, side effects, and overall health.
It is also important to remember that people using Tazverik were not all in the same situation. Someone with follicular lymphoma may have different backup options than someone with epithelioid sarcoma. Access can also differ depending on insurance, treatment center, and where a patient lives.
For now, the clearest practical steps are to contact the cancer team, review any symptoms quickly, and make sure you understand the plan for refills, monitoring, and treatment transition. Families and caregivers may need to help with phone calls, pharmacy coordination, transportation, and insurance paperwork during that change.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
